The tweet was deleted by the author.
But we saved everything 🙂.
Edgewise Therapeutics is set to present its strategic goals at the 44th Annual JPMorgan Healthcare Conference. Kevin Koch, Ph.D., CEO of Edgewise Therapeutics, will discuss the company's cardiovascular and muscular dystrophy programs and lay out key milestones for 2026. The event is scheduled for January 13 at 8:15 AM PST, providing insights into the company’s future directions and priorities.
This presentation comes as the healthcare sector continues to navigate various challenges and opportunities. Attendees can expect a detailed overview of the company’s initiatives aimed at advancing treatment options in cardiovascular health and muscular dystrophy, two critical areas with high unmet medical needs. For additional information, stakeholders are encouraged to read the full press release available on the company’s website.